Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats
Abstract
Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log 10 CFU/gram of bone, respectively.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2019
- Source ID
- 10.1128/aac.01235-19
Entities
People
- Cara Cassino
- Dario Lehoux
- Jayawant Mandrekar
- Kerryl E. Greenwood-quaintance
- Melissa J. Karau
- Qun Yan
- Raymond Schuch
- Robin Patel
- Suzannah M. Schmidt-malan
Organizations
- Central South University
- Mayo Clinic